Elsevier, European Journal of Cancer, (88), p. 1-9, 2018
DOI: 10.1016/j.ejca.2017.10.029
Full text: Unavailable
Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate biomarkers to easily and reliably determine it. The aim of this study was to assess the potential of plasma total cell free DNA as biomarker of tumour burden and prognosis in metastatic melanoma patients.